Acer Therapeutics to Virtually Present at Upcoming Investor Conferences
Acer Therapeutics Inc. (Nasdaq: ACER) announced a virtual corporate overview for September, 2020, at the LD Micro 500 Virtual Conference and H.C. Wainwright 22nd Annual Global Investment Conference. The LD Micro event is scheduled for September 1, 2020, at 3 p.m. ET, while the H.C. Wainwright conference will occur on September 15, 2020, at 2:30 p.m. ET. Acer focuses on therapies for serious rare diseases, featuring a pipeline that includes options for COVID-19 and various genetic disorders. More details are available on their website.
- None.
- None.
NEWTON, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will provide a virtual corporate overview at upcoming investor conferences in September, including the LD Micro 500 Virtual Conference and the H.C. Wainwright 22nd Annual Global Investment Conference.
Acer Conference Presentation Details:
| Conference: | LD Micro 500 Virtual Conference | |
| Date: | Tuesday, September 1, 2020 | |
| Time: | 3 p.m. Eastern Time | |
| Conference: | H.C. Wainwright 22nd Annual Global Investment Conference | |
| Date: | Tuesday, September 15, 2020 | |
| Time: | 2:30 p.m. Eastern Time | |
More information on Acer presentations can be found in the “Events and Presentations” section of Acer’s website at https://www.acertx.com/investor-relations/events-presentations/.
About Acer Therapeutics Inc.
Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer’s pipeline includes four clinical-stage candidates: emetine hydrochloride for the treatment of patients with COVID-19; ACER-001 (a taste-masked, immediate release formulation of sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and osanetant for the treatment of induced Vasomotor Symptoms (iVMS). Each of Acer’s product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA. For more information, visit www.acertx.com.
Investor Contact:
Hans Vitzthum
LifeSci Advisors
Ph: 617-430-7578
hans@lifesciadvisors.com
Jim DeNike
Acer Therapeutics Inc.
Ph: 844-902-6100
jdenike@acertx.com
FAQ
What are the details of Acer Therapeutics' upcoming conferences in September 2020?
What is the focus of Acer Therapeutics as a company?
What is included in Acer's product pipeline?
Where can I find more information about Acer Therapeutics' presentations?
